ITGAX and neoplasm: demonstrated that CD11b+Gr-1+ cells from tumor-bearing mice can differentiate in vitro into functional CD11c+ cells (which are capable of generating cytotoxic T lymphocytes) or F4⁄80+ suppressor macrophages when Th1 cytokines and tumor-derived cytokines are present in the microenvironment, which, in turn, activates immune responses [99].